abYsis: Integrated Antibody Sequence and Structure-Management, Analysis, and Prediction.

[1]  D. Xuan,et al.  Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach , 2016, Clinical pharmacology and therapeutics.

[2]  T. Torres,et al.  A revolutionary therapeutic approach for psoriasis: bispecific biological agents , 2016, Expert opinion on investigational drugs.

[3]  J. Guenot,et al.  Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia , 2016, Clinical Cancer Research.

[4]  Sebastian Kelm,et al.  SAbPred: a structure-based antibody prediction server , 2016, Nucleic Acids Res..

[5]  Charlotte M. Deane,et al.  ANARCI: antigen receptor numbering and receptor classification , 2015, Bioinform..

[6]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[7]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[8]  Patrice Duroux,et al.  IMGT®, the international ImMunoGeneTics information system® 25 years on , 2014, Nucleic Acids Res..

[9]  Anna Tramontano,et al.  Tabhu: tools for antibody humanization , 2014, Bioinform..

[10]  Andrew C. R. Martin.  Viewing multiple sequence alignments with the JavaScript Sequence Alignment Viewer (JSAV) , 2014, F1000Research.

[11]  Brian D. Weitzner,et al.  Blind prediction performance of RosettaAntibody 3.0: Grafting, relaxation, kinematic loop modeling, and full CDR optimization , 2014, Proteins.

[12]  Juan C Almagro,et al.  Second antibody modeling assessment (AMA‐II) , 2014, Proteins.

[13]  Haruki Nakamura,et al.  High‐resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations , 2014, Proteins.

[14]  Manuel Berrondo,et al.  Automated Aufbau of antibody structures from given sequences using Macromoltek's SmrtMolAntibody , 2014, Proteins.

[15]  R. Ladner,et al.  Drugs derived from phage display , 2014, mAbs.

[16]  Jiye Shi,et al.  SAbDab: the structural antibody database , 2013, Nucleic Acids Res..

[17]  J. Sussman,et al.  JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia , 2013 .

[18]  Anna Tramontano,et al.  A database of immunoglobulins with integrated tools: DIGIT , 2011, Nucleic Acids Res..

[19]  Taketo Yamada.  Therapeutic monoclonal antibodies. , 2011, The Keio journal of medicine.

[20]  Andrew C. R. Martin,et al.  Analysis and prediction of VH/VL packing in antibodies. , 2010, Protein engineering, design & selection : PEDS.

[21]  Andrew C. R. Martin,et al.  The humanness of macaque antibody sequences. , 2010, Journal of molecular biology.

[22]  Jan Berka,et al.  Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.

[23]  A. Lawson,et al.  High-Throughput Screening for High Affinity Antibodies , 2009 .

[24]  Jeffrey J. Gray,et al.  RosettaAntibody: antibody variable region homology modeling server , 2009, Nucleic Acids Res..

[25]  K. Bagshawe.  Targeting: the ADEPT story so far. , 2009, Current drug targets.

[26]  Paolo Marcatili,et al.  PIGS: automatic prediction of antibody structures , 2008, Bioinform..

[27]  Andrew C. R. Martin,et al.  Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. , 2008, Molecular immunology.

[28]  Andrew C. R. Martin,et al.  Analyzing the "degree of humanness" of antibody sequences. , 2007, Journal of molecular biology.

[29]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[30]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[31]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[32]  Mats Ohlin,et al.  Length of the antibody heavy chain complementarity determining region 3 as a specificity‐determining factor , 2004, Journal of molecular recognition : JMR.

[33]  Andrew C. R. Martin,et al.  Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. , 2003, Journal of molecular biology.

[34]  Inger Sandlie,et al.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.

[35]  I. Bernstein,et al.  Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.

[36]  L. Presta.  Engineering antibodies for therapy. , 2002, Current pharmaceutical biotechnology.

[37]  Andrew C. R. Martin,et al.  SACS-Self-maintaining database of antibody crystal structure information , 2002, Bioinform..

[38]  George Johnson,et al.  Kabat Database and its applications: future directions , 2001, Nucleic Acids Res..

[39]  P. Delves,et al.  The Immune System , 2000 .

[40]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[41]  M. Eaman.  Immune system. , 2000, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[42]  L. Green,et al.  Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. , 1999, Journal of immunological methods.

[43]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[44]  R. Freeman,et al.  A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation , 1999, Pharmacotherapy.

[45]  S. Hanauer,et al.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. , 1999, Inflammatory bowel diseases.

[46]  G. Johnson,et al.  Preferred CDRH3 lengths for antibodies with defined specificities. , 1998, International immunology.

[47]  O. Ramilo,et al.  Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia , 1998 .

[48]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[49]  Andrew J. Martin,et al.  Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. , 1996, Journal of molecular biology.

[50]  Andrew J. Martin,et al.  Antibody-antigen interactions: contact analysis and binding site topography. , 1996, Journal of molecular biology.

[51]  Andrew C. R. Martin,et al.  Accessing the Kabat antibody sequence database by computer , 1996, Proteins.

[52]  T. T. Wu,et al.  Length distribution of CDRH3 in antibodies , 1993, Proteins.

[53]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[54]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[55]  C. Milstein,et al.  Reshaping human antibodies: grafting an antilysozyme activity. , 1988, Science.

[56]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[57]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[58]  L. M. Smith,et al.  Human immune response to multiple injections of murine monoclonal IgG. , 1985, Journal of immunology.

[59]  K. Foon,et al.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. , 1985, Cancer research.

[60]  S. Rudikoff,et al.  VL-VH expression by monoclonal antibodies recognizing avian lysozyme. , 1984, Journal of immunology.

[61]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[62]  S. Cohen,et al.  Antibody structure , 2006 .